10.1371/journal.pone.0190638.g004 Yoo Jin Choi Yoo Jin Choi Seong-Joon Park Seong-Joon Park You-Soo Park You-Soo Park Hee Sung Park Hee Sung Park Kwang Mo Yang Kwang Mo Yang Kyu Heo Kyu Heo Characterization of the EpCAM peptide-specific CTL responses against HepG2 CSCs. Public Library of Science 2018 peptide-T 2 binding assay EpCAM peptides anti-tumor immunity HLA-A 2 molecules antigen CTL CSC marker MHC cytotoxic T lymphocytes HCC CD 44 T cell stimulation breast cancer EpCAM peptide-primed dendritic cell vaccination TAA hepatocellular carcinoma cells Cancer stem-like cells DC 2018-01-03 18:38:33 Figure https://plos.figshare.com/articles/figure/Characterization_of_the_EpCAM_peptide-specific_CTL_responses_against_HepG2_CSCs_/5755047 <p>(A) IFN-γ release by antigen-specific CTLs stimulated by antigens. Naïve T cells stimulated by co-culturing with tumor antigen-pulsed DCs were analyzed by ELISA for their production of IFN-γ. (B and C) Results from a cytotoxicity assay of CD8<sup>+</sup> T cells activated by tumor antigen-pulsed DCs. Different DCs were co-cultured at a ratio of 1:5 with lymphocytes for 5 days. The non-adherent cells were collected and counted as effector cells. The effector cells were co-cultured with the EpCAM positive (B) and EpCAM negative (C) HepG2 cells at different ratios for 6 h at 37°C in a 5% CO<sub>2</sub> incubator. The data are expressed as the mean±SD, and significant differences between the treated groups were detected using ANOVA followed by the Dunnett’s test. <sup>#</sup> <i>p</i><0.05 compared with the DCs or DC-CTLs, and * <i>p</i><0.05 compared with the TL-CTLs.</p>